{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:21:01Z","timestamp":1790659261485,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Aging Mech Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hutchinson\u2013Gilford progeria syndrome (HGPS) is a rare genetic disorder that causes systemic accelerated aging in children. This syndrome is due to a mutation in the <jats:italic>LMNA<\/jats:italic> gene that leads to the production of a truncated and toxic form of lamin A called progerin. Because the balance between the A-type lamins is controlled by the RNA-binding protein SRSF1, we have hypothesized that its inhibition may have therapeutic effects for HGPS. For this purpose, we evaluated the antidiabetic drug metformin and demonstrated that 48\u2009h treatment with 5\u2009mmol\/l metformin decreases SRSF1 and progerin expression in mesenchymal stem cells derived from HGPS induced pluripotent stem cells (HGPS MSCs). The effect of metformin on progerin was then confirmed in several <jats:italic>in vitro<\/jats:italic> models of HGPS, i.e., human primary HGPS fibroblasts, <jats:italic>Lmna<\/jats:italic><jats:sup><jats:italic>G609G\/G609G<\/jats:italic><\/jats:sup> mouse fibroblasts and healthy MSCs previously treated with a PMO (phosphorodiamidate morpholino oligonucleotide) that induces progerin. This was accompanied by an improvement in two <jats:italic>in vitro<\/jats:italic> phenotypes associated with the disease: nuclear shape abnormalities and premature osteoblastic differentiation of HGPS MSCs. Overall, these results suggest a novel approach towards therapeutics for HGPS that can be added to the currently assayed treatments that target other molecular defects associated with the disease.<\/jats:p>","DOI":"10.1038\/npjamd.2016.26","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T10:12:21Z","timestamp":1478772741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Metformin decreases progerin expression and alleviates pathological defects of Hutchinson\u2013Gilford progeria syndrome cells"],"prefix":"10.1038","volume":"2","author":[{"given":"Anne-Laure","family":"Egesipe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lo Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Laure","family":"Jaskowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara De","family":"Sandre-Giovannoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Peschanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-6274","authenticated-orcid":false,"given":"Xavier","family":"Nissan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"BFnpjamd201626_CR1","doi-asserted-by":"crossref","first-page":"16321","DOI":"10.1016\/S0021-9258(19)85424-8","volume":"268","author":"F Lin","year":"1993","unstructured":"Lin, F. & Worman, H. J. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. J. Biol. Chem. 268, 16321\u201316326 (1993).","journal-title":"J. Biol. Chem."},{"key":"BFnpjamd201626_CR2","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1126\/science.1084125","volume":"300","author":"A De Sandre-Giovannoli","year":"2003","unstructured":"De Sandre-Giovannoli, A. et al. Lamin a truncation in Hutchinson-Gilford progeria. Science 300, 2055 (2003).","journal-title":"Science"},{"key":"BFnpjamd201626_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nature01629","volume":"423","author":"M Eriksson","year":"2003","unstructured":"Eriksson, M. et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293\u2013298 (2003).","journal-title":"Nature"},{"key":"BFnpjamd201626_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1056\/NEJMoa0706898","volume":"358","author":"MA Merideth","year":"2008","unstructured":"Merideth, M. A. et al. Phenotype and course of Hutchinson-Gilford progeria syndrome. N. Engl. J. Med. 358, 592\u2013604 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnpjamd201626_CR5","doi-asserted-by":"publisher","first-page":"12873","DOI":"10.1073\/pnas.0505767102","volume":"102","author":"JI Toth","year":"2005","unstructured":"Toth, J. I. et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc. Natl Acad. Sci. USA 102, 12873\u201312878 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnpjamd201626_CR6","doi-asserted-by":"publisher","first-page":"16666","DOI":"10.1073\/pnas.1202529109","volume":"109","author":"LB Gordon","year":"2012","unstructured":"Gordon, L. B. et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc. Natl Acad. Sci. USA 109, 16666\u201316671 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnpjamd201626_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.113.008285","volume":"130","author":"LB Gordon","year":"2014","unstructured":"Gordon, L. B. et al. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 130, 27\u201334 (2014).","journal-title":"Circulation"},{"key":"BFnpjamd201626_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nm1786","volume":"14","author":"I Varela","year":"2008","unstructured":"Varela, I. et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14, 767\u2013772 (2008).","journal-title":"Nat. Med."},{"key":"BFnpjamd201626_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nm1204","volume":"11","author":"P Scaffidi","year":"2005","unstructured":"Scaffidi, P. & Misteli, T. Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat. Med. 11, 440\u2013445 (2005).","journal-title":"Nat. Med."},{"key":"BFnpjamd201626_CR10","doi-asserted-by":"publisher","first-page":"106ra107","DOI":"10.1126\/scitranslmed.3002847","volume":"3","author":"FG Osorio","year":"2011","unstructured":"Osorio, F. G. et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci. Transl. Med. 3, 106ra107 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnpjamd201626_CR11","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1172\/JCI85908","volume":"126","author":"JM Lee","year":"2016","unstructured":"Lee, J. M. et al. Modulation of LMNA splicing as a strategy to treat prelamin A diseases. J. Clin. Invest. 126, 1592\u20131602 (2016).","journal-title":"J. Clin. Invest."},{"key":"BFnpjamd201626_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/humu.22945","volume":"37","author":"V Vautrot","year":"2016","unstructured":"Vautrot, V. et al. Enhanced SRSF5 protein expression reinforces lamin A mRNA production in HeLa cells and fibroblasts of progeria patients. Hum. Mutat. 37, 280\u2013291 (2016).","journal-title":"Hum. Mutat."},{"key":"BFnpjamd201626_CR13","first-page":"89ra58","volume":"3","author":"K Cao","year":"2011","unstructured":"Cao, K. et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci. Transl. Med. 3, 89ra58 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnpjamd201626_CR14","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1093\/hmg\/ddr385","volume":"20","author":"IC Lopez-Mejia","year":"2011","unstructured":"Lopez-Mejia, I. C. et al. A conserved splicing mechanism of the LMNA gene controls premature aging. Hum. Mol. Genet. 20, 4540\u20134555 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"BFnpjamd201626_CR15","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.ccr.2011.10.016","volume":"20","author":"EM Amin","year":"2011","unstructured":"Amin, E. M. et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 20, 768\u2013780 (2011).","journal-title":"Cancer Cell"},{"key":"BFnpjamd201626_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/bjc.2014.342","volume":"111","author":"MV Gammons","year":"2014","unstructured":"Gammons, M. V. et al. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br. J. Cancer 111, 477\u2013485 (2014).","journal-title":"Br. J. Cancer"},{"key":"BFnpjamd201626_CR17","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1167\/iovs.13-12422","volume":"54","author":"MV Gammons","year":"2013","unstructured":"Gammons, M. V. et al. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Invest. Ophthalmol. Vis. Sci. 54, 6052\u20136062 (2013).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"BFnpjamd201626_CR18","doi-asserted-by":"publisher","first-page":"8977","DOI":"10.1073\/pnas.1201689109","volume":"109","author":"O Larsson","year":"2012","unstructured":"Larsson, O. et al. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc. Natl Acad. Sci. USA 109, 8977\u20138982 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnpjamd201626_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.5966\/sctm.2013-0168","volume":"3","author":"S Blondel","year":"2014","unstructured":"Blondel, S. et al. Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with hutchinson-gilford progeria syndrome. Stem Cells Transl. Med. 3, 510\u2013519 (2014).","journal-title":"Stem Cells Transl. Med."},{"key":"BFnpjamd201626_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.arr.2015.10.002","volume":"24","author":"A Lo Cicero","year":"2015","unstructured":"Lo Cicero, A. & Nissan, X. Pluripotent stem cells to model Hutchinson-Gilford progeria syndrome (HGPS): current trends and future perspectives for drug discovery. Ageing Res. Rev. 24, 343\u2013348 (2015).","journal-title":"Ageing Res. Rev."},{"key":"BFnpjamd201626_CR21","doi-asserted-by":"publisher","first-page":"e2105","DOI":"10.1038\/cddis.2015.374","volume":"7","author":"S Blondel","year":"2016","unstructured":"Blondel, S. et al. Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. Cell Death Dis. 7, e2105 (2016).","journal-title":"Cell Death Dis."},{"key":"BFnpjamd201626_CR22","doi-asserted-by":"publisher","first-page":"e98306","DOI":"10.1371\/journal.pone.0098306","volume":"9","author":"YB Luo","year":"2014","unstructured":"Luo, Y. B. et al. Antisense oligonucleotide induction of progerin in human myogenic cells. PLoS ONE 9, e98306 (2014).","journal-title":"PLoS ONE"},{"key":"BFnpjamd201626_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/ncb1708","volume":"10","author":"P Scaffidi","year":"2008","unstructured":"Scaffidi, P. & Misteli, T. Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat. Cell Biol. 10, 452\u2013459 (2008).","journal-title":"Nat. Cell Biol."},{"key":"BFnpjamd201626_CR24","doi-asserted-by":"publisher","first-page":"10291","DOI":"10.1073\/pnas.0504641102","volume":"102","author":"SH Yang","year":"2005","unstructured":"Yang, S. H. et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc. Natl Acad. Sci. USA 102, 10291\u201310296 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnpjamd201626_CR25","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1194\/jlr.M002808","volume":"51","author":"SH Yang","year":"2010","unstructured":"Yang, S. H. et al. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria. J. Lipid Res. 51, 400\u2013405 (2010).","journal-title":"J. Lipid Res."},{"key":"BFnpjamd201626_CR26","doi-asserted-by":"crossref","unstructured":"Kubben N., Brimacombe K. R., Donegan M., Li Z. & Misteli T. A high-content imaging-based screening pipeline for the systematic identification of anti-progeroid compounds. Methods 96, 46\u201358 (2016).","DOI":"10.1016\/j.ymeth.2015.08.024"},{"key":"BFnpjamd201626_CR27","doi-asserted-by":"publisher","first-page":"e8758","DOI":"10.1371\/journal.pone.0008758","volume":"5","author":"B Onken","year":"2010","unstructured":"Onken, B. & Driscoll, M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS ONE 5, e8758 (2010).","journal-title":"PLoS ONE"},{"key":"BFnpjamd201626_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cell.2013.02.035","volume":"153","author":"F Cabreiro","year":"2013","unstructured":"Cabreiro, F. et al. Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism. Cell 153, 228\u2013239 (2013).","journal-title":"Cell"},{"key":"BFnpjamd201626_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000212423","volume":"26","author":"VM Dilman","year":"1980","unstructured":"Dilman, V. M. & Anisimov, V. N. Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H\/Sn mice. Gerontology 26, 241\u2013246 (1980).","journal-title":"Gerontology"},{"key":"BFnpjamd201626_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s10517-005-0389-9","volume":"139","author":"VN Anisimov","year":"2005","unstructured":"Anisimov, V. N. et al. Metformin decelerates aging and development of mammary tumors in HER-2\/neu transgenic mice. Bull. Exp. Biol. Med. 139, 721\u2013723 (2005).","journal-title":"Bull. Exp. Biol. Med."},{"key":"BFnpjamd201626_CR31","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.4161\/cc.7.17.6625","volume":"7","author":"VN Anisimov","year":"2008","unstructured":"Anisimov, V. N. et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 7, 2769\u20132773 (2008).","journal-title":"Cell Cycle"},{"key":"BFnpjamd201626_CR32","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","volume":"170","author":"R Roussel","year":"2010","unstructured":"Roussel, R. et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch. Intern. Med. 170, 1892\u20131899 (2010).","journal-title":"Arch. Intern. Med."},{"key":"BFnpjamd201626_CR33","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1161\/CIRCULATIONAHA.106.611707","volume":"114","author":"FA Masoudi","year":"2006","unstructured":"Masoudi, F. A. et al. Trends in acute myocardial infarction in 4 US states between 1992 and 2001: clinical characteristics, quality of care, and outcomes. Circulation 114, 2806\u20132814 (2006).","journal-title":"Circulation"},{"key":"BFnpjamd201626_CR34","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/dom.12354","volume":"16","author":"CA Bannister","year":"2014","unstructured":"Bannister, C. A. et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes. Metab. 16, 1165\u20131173 (2014).","journal-title":"Diabetes Obes. Metab."},{"key":"BFnpjamd201626_CR35","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1126\/science.1127168","volume":"312","author":"P Scaffidi","year":"2006","unstructured":"Scaffidi, P. & Misteli, T. Lamin A-dependent nuclear defects in human aging. Science 312, 1059\u20131063 (2006).","journal-title":"Science"},{"key":"BFnpjamd201626_CR36","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1172\/JCI43578","volume":"121","author":"K Cao","year":"2011","unstructured":"Cao, K. et al. Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts. J. Clin. Invest. 121, 2833\u20132844 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnpjamd201626_CR37","doi-asserted-by":"publisher","first-page":"e1269","DOI":"10.1371\/journal.pone.0001269","volume":"2","author":"D McClintock","year":"2007","unstructured":"McClintock, D. et al. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS ONE 2, e1269 (2007).","journal-title":"PLoS ONE"},{"key":"BFnpjamd201626_CR38","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u2013872 (2007).","journal-title":"Cell"},{"key":"BFnpjamd201626_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2012.05.015","volume":"2","author":"X Nissan","year":"2012","unstructured":"Nissan, X. et al. Unique preservation of neural cells in Hutchinson-Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA. Cell Rep. 2, 1\u20139 (2012).","journal-title":"Cell Rep."},{"key":"BFnpjamd201626_CR40","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/ejhg.2008.270","volume":"17","author":"S Rodriguez","year":"2009","unstructured":"Rodriguez, S., Copped\u00e8, F., Sagelius, H. & Eriksson, M. Increased expression of the Hutchinson-Gilford progeria syndrome truncated lamin A transcript during cell aging. Eur. J. Hum. Genet. 17, 928\u2013937 (2009).","journal-title":"Eur. J. Hum. Genet."}],"container-title":["npj Aging and Mechanisms of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/npjamd201626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjamd201626","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/npjamd201626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T12:14:37Z","timestamp":1672834477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/npjamd201626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,15]]}},"alternative-id":["BFnpjamd201626"],"URL":"https:\/\/doi.org\/10.1038\/npjamd.2016.26","relation":{},"ISSN":["2056-3973"],"issn-type":[{"value":"2056-3973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]},"assertion":[{"value":"20 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16026"}}